Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer

PURPOSE: The EndoPredict prognostic assay is validated to predict distant recurrence and response to chemotherapy primarily in post-menopausal women with estrogen receptor–positive (ER(+)), HER2(−) breast cancer. This study evaluated the performance of EndoPredict in pre-menopausal women. EXPERIMENT...

Descripción completa

Detalles Bibliográficos
Autores principales: Constantinidou, Anastasia, Marcou, Yiola, Toss, Michael S., Simmons, Timothy, Bernhisel, Ryan, Hughes, Elisha, Probst, Braden, Meek, Stephanie, Kakouri, Eleni, Georgiou, Georgios, Zouvani, Ioanna, Savvidou, Gabriella, Kuhl, Vanessa, Doedt, Jennifer, Wagner, Susanne, Gutin, Alexander, Slavin, Thomas P., Lanchbury, Jerry S., Kronenwett, Ralf, Ellis, Ian O., Rakha, Emad A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Precision Medicine and Imaging
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561607/
https://www.ncbi.nlm.nih.gov/pubmed/36043530
http://dx.doi.org/10.1158/1078-0432.CCR-22-0619

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561607/
https://www.ncbi.nlm.nih.gov/pubmed/36043530
http://dx.doi.org/10.1158/1078-0432.CCR-22-0619

Ejemplares similares